Pentadienoyl piperidine derivative and use thereof

US10100011B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10100011-B2
Application numberUS-201515513072-A
CountryUS
Kind codeB2
Filing dateSep 22, 2015
Priority dateSep 23, 2014
Publication dateOct 16, 2018
Grant dateOct 16, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to a novel pentadienoyl piperidine derivative, a pharmaceutical composition containing the same for prevention or treatment of metabolic diseases, and a functional food composition using the same for improvement or relief of metabolic diseases. The pentadienoyl piperidine derivative of the present invention inhibits the differentiation of preadipocytes, reduces body weight, visceral fat, blood lipid levels, and blood glucose levels, improves a blood liver function index, and suppresses metabolic inflammation responses. Thus, ultimately, the derivative can be usefully used as a medicine or a functional food composition, which exhibits the preventive or therapeutic activity for metabolic diseases selected from the group consisting of obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome.

First claim

Opening claim text (preview).

The invention claimed is: 1. A pentadienoyl piperidine derivative represented by Formula 1 below or a pharmaceutically acceptable salt thereof: wherein R 1 is a C 1 -C 3 alkyl group. 2. The pentadienoyl piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 1 of Formula 1 is a methyl group. 3. A pharmaceutical composition for treatment of metabolic diseases, wherein the pharmaceutical composition comprises the pentadienoyl piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient and the metabolic diseases are selected from the group consisting of obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome. 4. The pharmaceutical composition according to claim 3 , wherein the dyslipidemia is hyperlipidemia. 5. The pharmaceutical composition according to claim 3 , wherein the fatty liver is non-alcoholic fatty liver. 6. The pharmaceutical composition according to claim 3 , wherein the composition reduces the differentiation of adipocytes. 7. The pharmaceutical composition according to claim 3 , wherein the composition reduces blood fat, liver fat or visceral fat. 8. The pharmaceutical composition according to claim 7 , wherein the visceral fat comprises one or more selected from the group consisting of epididymal fat, perirenal fat, mesenteric fat and retroperitoneal fat. 9. The pharmaceutical composition according to claim 3 , the composition reduces the activity of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) in blood. 10. A food composition for improvement or relief of metabolic diseases, wherein the food composition comprises the pentadienoyl piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient and the metabolic diseases are selected from the group consisting of obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome. 11. A method of improving or treating metabolic diseases, wherein the method comprises a step of administrating a composition comprising the pentadienoyl piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient to a subject in need and the metabolic diseases are selected from the group consisting of obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome.

Assignees

Inventors

Classifications

  • for hyperglycaemia, e.g. antidiabetics · CPC title

  • C07D211/32Primary

    by oxygen atoms · CPC title

  • only substituted in position 1, e.g. propipocaine, diperodon · CPC title

  • Anorexiants; Antiobesity agents · CPC title

  • Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10100011B2 cover?
The present invention relates to a novel pentadienoyl piperidine derivative, a pharmaceutical composition containing the same for prevention or treatment of metabolic diseases, and a functional food composition using the same for improvement or relief of metabolic diseases. The pentadienoyl piperidine derivative of the present invention inhibits the differentiation of preadipocytes, reduces bod…
Who is the assignee on this patent?
Univ Yonsei Iacf, Snu R&Db Foundation
What technology area does this patent fall under?
Primary CPC classification C07D211/32. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Oct 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).